孕妇GBS免疫接种的成本效果分析:模型研究
本研究用决策树模型评估英国孕妇接种GBS疫苗预防新生儿和母亲侵袭性GBS疾病的成本效果,时间跨度81年。确定性分析显示在每QALY 2万英镑阈值下疫苗每剂成本效果阈值为54英镑,概率分析显示疫苗价格55英镑时90.66%的模拟低于3万英镑阈值。结论认为孕妇GBS免疫接种预期具有成本效果。
要点
- 确定性分析:每QALY 2万英镑阈值下疫苗每剂成本效果阈值为54英镑。
- 每QALY 3万英镑阈值下疫苗每剂成本效果阈值为71英镑。
- 疫苗价格55英镑时90.66%概率分析模拟低于3万英镑阈值。
核心结论
- 孕妇GBS免疫接种预期具有成本效果,即使疫苗价格相对较高。
研究设计与样本
- 决策树模型涵盖婴儿和母亲GBS相关事件,随访出生队列至平均预期寿命81年,参数来自疾病监测和GBS幸存者结局数据,成本来自NHS来源和研究。
主要发现
- 有效的孕妇免疫规划可大幅降低GBS疾病负担。
- 确定性分析估计每QALY 2万英镑阈值下疫苗每剂成本效果阈值为54英镑,每QALY 3万英镑阈值下为71英镑。
- 结果对疾病发病率、后遗症率和疫苗效力的假设最敏感。
- 概率分析显示疫苗价格55英镑时90.66%的模拟低于3万英镑阈值。
- 纳入对死产和/或早产的适度预防、照护者健康影响、母亲GBS死亡及1.5%贴现可改善成本效果;降低疫苗株覆盖率则成本效果变差。
关键数值与推荐
- 每QALY 2万英镑阈值下疫苗每剂成本效果阈值为54英镑。
- 每QALY 3万英镑阈值下疫苗每剂成本效果阈值为71英镑。
- 疫苗价格55英镑时90.66%的概率分析模拟低于3万英镑阈值。
临床怎么用
- 孕妇GBS免疫接种可与基于风险的产时抗生素预防(IAP)联合使用,替代当前单独基于风险的IAP标准实践。
局限性
- 最终GBS疫苗的特性未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is a considerable global burden of invasive group B streptococcal (GBS) disease. Vaccines are being developed for use in pregnant women to offer protection to neonates. OBJECTIVE: To estimate the potential impact and cost-effectiveness of maternal immunisation against neonatal and maternal invasive GBS disease in the UK. METHODS: We developed a decision-tree model encompassing GBS-related events in infants and mothers, following a birth cohort with a time horizon equivalent to average life expectancy (81 years). We parameterised the model using contemporary data from disease surveillance and outcomes in GBS survivors. Costs were taken from NHS sources and research studies. Maternal immunisation in combination with risk-based intrapartum antibiotic prophylaxis (IAP) was compared to the current standard practice of risk-based IAP alone from an NHS and Personal Social Services (health-provider) perspective. We estimated the cases averted and cost per QALY gained through vaccination. One-way sensitivity analysis, scenario analysis and probabilistic sensitivity analysis were performed. RESULTS: An effective maternal immunisation programme could substantially reduce the burden of GBS disease. The deterministic analysis estimated the threshold cost-effective price for a GBS vaccine to be £54 per dose at £20,000/QALY (£71 per dose at £30,000/QALY). Results were most sensitive to assumptions on disease incidence, sequelae rate and vaccine efficacy. Probabilistic analysis showed 90.66% of iterations fell under the £30,000 threshold at a vaccine price of £55. Inclusion of modest prevention of stillbirths and/or, preterm births, carer health impacts, maternal GBS deaths and 1.5% discounting improved cost-effectiveness compared to the base case. Lowering vaccine strain coverage made the vaccine less cost-effective. A key limitation is that the properties of the final GBS vaccine are unknown. CONCLUSIONS: Maternal GBS immunisation is expected to be cost-effective, even at a relatively high vaccine price.
引用
- Giorgakoudi K, O'Sullivan C, Heath PT, et al. Cost-effectiveness analysis of maternal immunisation against group B Streptococcus (GBS) disease: A modelling study. Vaccine. 2018. PMID: 30293765. doi:10.1016/j.vaccine.2018.09.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。